<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17001">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885558</url>
  </required_header>
  <id_info>
    <org_study_id>47880</org_study_id>
    <nct_id>NCT02885558</nct_id>
  </id_info>
  <brief_title>Role of Calcium Channels in Vascular Function</brief_title>
  <official_title>Role of T-type Calcium Channels in Vascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the role of T-type calcium channels in endothelial
      dysfunction observed with ageing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>Hemodynamic response to femoral arterially infused vasoactive substances</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Endothelium, Vascular</condition>
  <arm_group>
    <arm_group_label>L + T-type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Type</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L + T-type</intervention_name>
    <description>8 weeks treatment with either efonidipine</description>
    <arm_group_label>L + T-type</arm_group_label>
    <other_name>Landel (efonidipine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Type</intervention_name>
    <description>8 weeks treatment with either nifedipine</description>
    <arm_group_label>L-Type</arm_group_label>
    <other_name>Adalat (nifedipine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 20 - 30 and 60-70

          -  BMI &lt; 30

        Exclusion Criteria:

          -  Hypertension (&gt;150/90 mmHg)

          -  Smoking

          -  Physical activity &gt;2 hours/week

          -  Known chronic diseases

          -  Pregnancy or birth within 3 month

          -  Alcohol misuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre for Phsical Activity Research</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan P Mortensen, DMSc</last_name>
      <email>smortensen@health.sdu.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular and Renal Research</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan P Mortensen, DMSc</last_name>
      <email>smortensen@health.sdu.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>August 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Stefan Mortensen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Receptors, Calcium Channel Blocker</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Efonidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
